Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.306
Revised: January 1, 2014
Accepted: January 17, 2014
Published online: May 27, 2014
Core tip: The metabolic syndrome (MS) and its hepatic manifestations, non-alcoholic fatty liver disease (NAFLD), are increasingly observed in Western countries. Both MS and NAFLD could favor the development of primary liver malignancies and may also lead to end-stage liver disease. These patients are at higher operative risk because of underestimated postoperative liver related complications but also specific increase in cardio-vascular complications. Specific improvements in the perioperative management of these patients are required in order to improve the operative results.